Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.

Participants needed: 105
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Candid TherapeuticsUpdated: Jul 22, 2026Locations: 1
Eligibility criteria

18 to 65 years old [+10]

Inadequate clinical laboratory parameters at Screening [+21]

Read more
Status: Recruiting

A Clinical Study of Cizutamig in Thyroid Eye Disease

The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).

Participants needed: 38
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Candid TherapeuticsUpdated: May 19, 2026Locations: 1
Eligibility criteria

18-75 years old at the time of signing the Informed Consent Form [+1]

Inadequate clinical laboratory parameters at Screening [+11]

Read more
Status: Recruiting

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus

Participants needed: 47
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Candid TherapeuticsUpdated: Nov 17, 2025Locations: 1
Eligibility criteria

18 to 75 years old at the time of signing the informed consent form [+6]

Inadequate clinical laboratory parameters at Screening [+19]

Read more
Status: Recruiting

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.

Participants needed: 44
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Candid TherapeuticsUpdated: Nov 17, 2025Locations: 1
Eligibility criteria

At least 18 years old at the time of signing the Informed Consent Form (ICF); [+3]

Any history of CAR-T or TCE therapy targeting any antigen or BCMA-targeted thera... [+10]

Read more